Silodyx Evropska unija - hrvaščina - EMA (European Medicines Agency)

silodyx

recordati ireland ltd - silodosin - prostata hyperplasia - urologicals - liječenje znakova i simptoma benigne hiperplazije prostate (bph).

Pluvicto Evropska unija - hrvaščina - EMA (European Medicines Agency)

pluvicto

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - tumori prostate, Кастраци-uporan - terapeutski radiofarmaceutski pripravci - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Nubeqa Evropska unija - hrvaščina - EMA (European Medicines Agency)

nubeqa

bayer ag - darolutamide - tumori prostate, Кастраци-uporan - endokrinska terapija - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

Cabazitaxel Accord Evropska unija - hrvaščina - EMA (European Medicines Agency)

cabazitaxel accord

accord healthcare s.l.u. - cabazitaxel - tumori prostate, Кастраци-uporan - antineoplastična sredstva - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Akeega Evropska unija - hrvaščina - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - tumori prostate, Кастраци-uporan - antineoplastična sredstva - treatment of adult patients with prostate cancer.

PROSTAMOL UNO 320 mg/1 kapsula kapsula, meka Bosna in Hercegovina - hrvaščina - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

prostamol uno 320 mg/1 kapsula kapsula, meka

berlin chemie / menarini bh d.o.o. sarajevo - ekstrakt ploda testeraste palme - kapsula, meka - 320 mg/1 kapsula - 1 kapsula, meka sadrži: ekstrakt ploda testeraste palme (serenoaw repentis fructus extractum) (911:1) 320 mg.

Silodosin Recordati Evropska unija - hrvaščina - EMA (European Medicines Agency)

silodosin recordati

recordati ireland ltd - silodosin - prostata hyperplasia - urologicals, alfa-antagonisti адренорецепторов - liječenje znakova i simptoma benigne простатической hiperplazija (bph) kod muškaraca u dobi od.

Locametz Evropska unija - hrvaščina - EMA (European Medicines Agency)

locametz

novartis europharm limited  - gozetotide - radionuklidno slikanje - dijagnostički radiofarmaceutici - ovaj je lijek samo za dijagnostičku uporabu. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Pylclari Evropska unija - hrvaščina - EMA (European Medicines Agency)

pylclari

curium pet france - piflufolastat (18f) - prostatske neoplazme - dijagnostički radiofarmaceutici - ovaj je lijek samo za dijagnostičku uporabu. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Axumin Evropska unija - hrvaščina - EMA (European Medicines Agency)

axumin

blue earth diagnostics ireland ltd - fluciclovine (18f) - prostatic neoplasms; radionuclide imaging - dijagnostički radiofarmaceutici - ovaj je lijek samo za dijagnostičku uporabu. axumin indiciran za pozitronska emisijska tomografija (pet) ct za otkrivanje recidiva raka prostate kod odraslih muškaraca sumnja na recidiv, na temelju povišeni krvni razine specifičnog antigena prostate (psa) nakon primarnog liječenja.